Rose, John B. MD*,; Finkel, Julia C. MD§,; Arquedas-Mohs, Adriano MD∥; Himelstein, Bruce P. MD†,; Schreiner, Mark MD*‡,; Medve, Robert A. MD¶
Departments of *Anesthesiology and Critical Care Medicine, and †Oncology, Children’s Hospital of Philadelphia and the University of Pennsylvania, School of Medicine; ‡Children’s Clinical Research Institute, Philadelphia, Pennsylvania; §Department of Anesthesiology, Children’s National Medical Center and George Washington University Medical Center, Washington, DC; ∥Instituto Costarricense De Investigaciones Clinicas, Costa Rica; and ¶The R.W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey
The Tram-Peds-008 study was funded by the R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ.
This work was presented in part at the American Society of Anesthesiologists Annual Meeting, New Orleans, October 2001.
October 7, 2002.
Address correspondence and reprint requests to John B. Rose, MD, Department of Anesthesiology and Critical Care Medicine, Children’s Hospital of Philadelphia, 34th St. & Civic Center Blvd., Philadelphia, PA 19104. Address e-mail to email@example.com.
There are few potent analgesic medications labeled for pediatric use. Tramadol is an atypical opioid structurally related to codeine whose unique mechanism of action involves both central inhibition of norepinephrine and serotonin reuptake coupled with a weak affinity of tramadol and its O-desmethyl metabolite for μ-opiate receptors (1–4). Since 1995, tramadol has been available in the United States in tablet form for use in adults. Based on worldwide experience in pediatric patients, tramadol has proven to be an effective and safe analgesic for postoperative, dental, and other pain (5–9). Little is known regarding the safety or efficacy of long-term use in children. We undertook this investigation to determine the safety profile of oral tramadol therapy for pain of 7–30 days’ duration in children. Efficacy measures were also assessed.
After obtaining IRB approval, informed parental consent, and patient assent, 7–16-yr-old children who were anticipated to require analgesics for 7–30 days, weighing >20 kg, and able to swallow tablets were enrolled. Children with a history of seizures, alcohol abuse, drug abuse, pregnancy, creatinine clearance <30 mL/min, or the use of CYP2D6 or CYP3A4 inhibitors (except amitriptyline, nortriptyline, and stable doses of selective serotonin reuptake inhibitors) were excluded from participation.
After a baseline medical history and physical examination, blood samples were obtained to determine serum alanine amino transferase, aspartate amino transferase, creatinine, blood urea nitrogen, sodium, potassium levels, hemoglobin, hematocrit, white blood cell count, and platelet count. Tramadol (50-mg scored tablets) 1 mg/kg orally every 4–6 h was started and increased if required (up to a maximum of 2 mg/kg per dose or 100 mg, not to exceed the lesser of 8 mg · kg−1 · d−1 or 400 mg/d). Parents recorded tramadol use on a diary card. Patients rated pain by using the Wong-Baker faces pain scale before, and 1 h after, dosing with tramadol, and recorded their scores on the diary card (10). Supplemental analgesics were permitted and prescribed at the discretion of the investigator if tramadol was inadequate to control pain.
Study compliance and adverse events (AEs) were assessed by telephone on day 3 and during a clinic visit on day 8. For patients continuing tramadol beyond 7 days, study compliance and AEs were assessed again by telephone on day 16 and during a final clinic visit after discontinuing tramadol therapy (no later than day 30 of therapy). During the final site visit, a physical examination and all laboratory evaluations were repeated, and the parents’ and the investigators’ overall assessment of drug efficacy was evaluated by using a 5-point scale (5-point scale: 1 = poor, 2 = fair, 3 = good, 4 = very good, and 5 = excellent). A final telephone interview was performed 2–4 days after the final site visit to assess AEs.
The sample size was based on evaluation of safety, and the trial was designed to ensure that at least 75 participants who completed 7 days of therapy and 8 participants who completed at least 14 days of therapy were enrolled. Efficacy was assessed by: the pain intensity difference calculated on days 1–8 (baseline pain score minus score 1 h postdosing); percentages of patients with less pain, no change, or more pain compared with baseline on days 1–8; percentages of subjects requiring supplemental analgesics; the total daily dose adjusted by body weight; and the parents’ and investigators’ overall assessment of tramadol as an analgesic. Safety and tolerability were assessed by summarizing all AEs by body system and by expressing all laboratory results and vital signs as change from baseline.
Safety and efficacy were evaluable in 113 of 114 patients enrolled. One subject was lost to follow-up. Twenty-three subjects withdrew before 7 days of therapy because of: resolution of pain (n = 11), AEs (n = 8), and patient choice (n = 4). Patient characteristics are provided in Table 1.
The average dose and mean duration of tramadol therapy were 3.0 ± 1.7 mg · kg−1 · d−1 and 11.2 ± 7.5 days, respectively. A total of 90, 28, and 9 patients completed 7, 14, and 30 days of tramadol therapy, respectively. Subjects completing 7 days of therapy discontinued tramadol because: an analgesic was no longer required (n = 60), completion of 29 days of therapy (n = 11), lack of efficacy (n = 6), subject or investigator choice (n = 6), AEs (n = 4), and subject required less potent analgesic (acetaminophen or ibuprofen, n = 3).
The mean Wong-Baker faces pain score before tramadol therapy on the first day of the study was 3.0 ± 1.3. However, almost all subjects were taking another analgesic medication at the time of enrollment and, therefore, this score does not represent the true baseline level of pain. On days 1–8, pain diminished 1 h after tramadol in 64%–78% of subjects (Table 2). The mean pain intensity difference by day ranged between 1.0 ± 1.1 to 1.4 ± 1.3 (Table 2). On at least one occasion during the study, 48% of subjects required supplemental analgesics. Tramadol was rated very good or excellent by 69% of parents and by 70% of investigators. The weighted κ of 0.658 (95% CI, 0.557–0.759) indicated good observer agreement among the parents/legal guardians and investigators.
There were no clinically important changes in vital signs. Changes in all serum chemistry and hematology variables were small and clinically insignificant. AEs were reported by 75 (66%) subjects and were similar regardless of length of therapy (Table 3). All AEs related to tramadol were rated as mild to moderate in severity. Only 12 subjects discontinued tramadol because of an AE.
The scarcity of approved potent analgesics labeled for children contributes to the under-treatment of pain in this age group. We have shown that tramadol was well tolerated by 7–16-year-old children with a variety of painful conditions for 7–30 days’ duration. AEs were generally considered to be mild or moderate in severity by investigators. The AE profile and, in particular, the incidence of nausea and vomiting observed, is similar to that reported in adult trials (11). Although the AE profile of tramadol is similar to that of other opioid analgesics, several reports indicate that respiratory depression is less severe with tramadol compared with other opiates (12–14). This may represent a significant advantage of tramadol in the treatment of pediatric pain.
In a previous companion trial, evidence for a dose response with tramadol in the treatment of pediatric postsurgical pain was established (15). A majority of subjects in the present study reported a reduction in pain within one hour of dosing, even though tramadol’s peak effect is not achieved until between two and three hours. The investigators decided that the pain assessment at one hour before the anticipated peak effect was necessary to accommodate the schedules of school-age children. The efficacy and safety of tramadol observed in this trial must be considered preliminary given the limitations of the open-label study design, the measures of efficacy used in this study, and absence of a comparator. Randomized, controlled trials are required to further clarify the analgesic efficacy and relative safety of tramadol compared with current alternatives and to explore the possible additive or synergistic effects of combination therapy with acetaminophen or nonsteroidal antiinflammatory drugs. In the meantime, the accumulating data about tramadol provide children with an important therapeutic option for treatment of pain.
Study concept and design: Medve, Schreiner, Lynn Schultz (RWJPRI); advisory board: Schmitz M, Finkel J, Walson P, Himelstein B, Rose J; acquisition of data, Tramadol-Peds-008 investigators: Rose J, Children’s Hospital of Philadelphia; Finkel J, Children’s National Medical Center, Washington, DC; Arguedas-Mohs A, Instituto Costarriccense De Investigaciones Costa Rica; Himelstein B, Children’s Hospital of Philadelphia; Jove M, Atlanta Knee and Sports Medicine; Goldsmith S, Clinical Studies Ltd., Florida; Thusu K, Lexington Biomedical Research, California; Luber S, Personal Practice, Washington; Rodarte A, Children’s Hospital of San Diego; Walson P, Columbus Children’s Hospital; Ostroc B, Hershey Medical Center; Nimityongkol P, University of South Alabama; McKinney R, Duke Children’s Hospital and Health Center; D’Sylva Y, Integrated Research Group, California; Mohyi L, Children’s Hospital of Orange County; Schmitz M, AR Children’s Hospital; Goldblatt E, Riverchase Clinical Research, Alabama; Perkins A, University of South Alabama; Bruce R, Emory University; Spencer C, Lutheran General Children’s Hospital; Malviya S, University of Michigan Health System; Simpser E, St. Mary’s Hospital for Children, New York; Phillips A, Health Advance, Medical Research Centers, Texas; Khalil S, University of Texas, Houston Health Science Center; Guinan E, Dana Farber Cancer Institute, Boston Children’s Hospital; and Leonard K, Hospital for Joint Diseases Orthopedic Institute, New York; drafting of the manuscript: Rose J; critical revision of the manuscript: Finkel, Schreiner, Rose, Himelstein; statistical expertise: Julia Wang (RWJPRI); administrative support: Meryl Polu (CCRI), Alice Poch (RWJPRI), Cheryl Impellizzeri (PAREXEL); study supervision: Schreiner, Medve.
1. Lewis KS, Han NH. Tramadol: a new centrally acting analgesic. Am J Health Syst Pharm 1997; 54: 643–52.
2. Raffa RB, Friderichs E, Reimann W, et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an “atypical” opioid analgesic. J Pharmcol Exp Ther 1992; 260: 275–85.
3. Hennies HH, Friderichs E, Schneider J. Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Drug Res 1988; 38: 877–80.
4. Dayer P, Collart L, Desmeules J. The pharmacology of tramadol. Drugs 1994; 47 (Suppl 1): 3–7.
5. Viitanen H, Annila P. Analgesic efficacy of tramadol 2 mg kg−1 for paediatric day-case adenoidectomy. Br J Anaesth 2001; 86: 572–5.
6. Senel AC, Akyol A, Dohman D, Solak M. Caudal bupivacaine-tramadol combination for postoperative analgesia in pediatric herniorrhaphy. Acta Anaesthesiol Scand 2001; 45: 786–9.
7. Prosser DP, Davis A, Booker PD, Murray A. Caudal tramadol for postoperative analgesia in paediatric hypospadias surgery. Br J Anaesth 1997; 79: 293–6.
8. Murthy BV, Pandya KS, Booker PD, et al. Pharmacokinetics of tramadol in children after IV or caudal administration. Br J Anaesth 2000; 84: 346–9.
9. Roelofse JA, Payne KA. Oral tramadol: analgesic efficacy in children following multiple dental extractions. Eur J Anaesthesiol 1999; 16: 441–7.
10. Whaley L, Wong D. Nursing care of infants and children. 4th ed. St. Louis: Mosby-Year Book, 1991: 1148.
11. Cossmann M, Kohnen C, Langford R, McCartney C. Tolerance and safety of tramadol use: results of international studies and data from drug surveillance [Review in French]. Drugs 1997; 53 (Suppl): 50–62.
12. Houmes RJ, Voets MA, Verkaaik A, et al. Efficacy and safety of tramadol versus morphine for moderate and severe postoperative pain with special regard to respiratory depression. Anesth Analg 1992; 74: 510–4.
13. Vickers MD, O’Flaherty D, Szekely SM, et al. Tramadol: pain relief by an opioid without depression of respiration. Anaesthesia 1992; 47: 291–6.
14. Bosenberg A, Ratcliffe S. The respiratory effects of tramadol in children under halothane anesthesia. Anaesthesia 1998; 53: 960–4.
15. Finkel JC, Rose JB, Schmitz ML, et al. An evaluation of the efficacy and tolerability of oral tramadol hydrochloride tablets for the treatment of postsurgical pain in children. Anesth Analg 2002; 94: 1469–73.
Submit Your Papers Online
You can now have your paper processed and reviewed faster by sending it to us through our new, web-based Rapid Review System. Submitting your manuscript online will mean that the time and expense of sending papers through the mail can be eliminated. Moreover, because our reviewers will also be working online, the entire review process will be significantly faster. You can submit manuscripts electronically via http://www.rapidreview.com. There are links to this site from the Anesthesia & Analgesia website (http://www.anesthesia-analgesia.org), and the IARS website (http://www.iars.org). To find out more about Rapid Review, go to http://www.rapidreview.com and click on “About Rapid Review.”